Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 4

3(60.0%)

Phase 2

2(40.0%)

5Total

Phase 4(3)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT04815967Phase 2Unknown

Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity

Role: collaborator

NCT04099667Phase 2Unknown

Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity

Role: collaborator

NCT00702754Phase 4Completed

An Open Label Safety and Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) Injectable Solution in Patients With Cervical Dystonia

Role: lead

NCT02052024Phase 4Completed

Myobloc Atrophy Study

Role: collaborator

NCT00208091Phase 4Completed

Quantifying Musical Performance After Treatment With Myobloc in Musician's Dystonia

Role: collaborator

All 5 trials loaded